SKIBSTED RUSSELL 4

What Happened
Skibsted Russell, Chief Financial Officer of Processa Pharmaceuticals (PCSA), reported an open-market purchase of 2,190 shares on April 30, 2026. The shares were bought at $2.69 per share, for a total reported outlay of $5,891. This was a purchase (transaction code P), which insiders’ buys can be of interest to investors as a sign of insider alignment with shareholders.

Key Details

• Transaction date and price: 2026-04-30 at $2.69 per share.
• Shares purchased: 2,190; total value reported: $5,891.
• Transaction type: Open-market purchase (code P).
• Filing date: Form 4 filed 2026-05-01 — timely (filed the next business day).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes/plan: No 10b5-1 plan, tax-withholding, or other special footnotes disclosed in the provided information.

Context
An open-market purchase means the insider bought shares on the public market rather than receiving a grant or exercising options. While insider purchases can signal confidence or alignment, this particular buy is modest in dollar size (~$5.9k) and may have limited market impact. Retail investors should treat small-dollar insider buys as one data point alongside company fundamentals and other filings.